CBPD-268

• Description :

  CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC50 value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Structure Note: Red, Androgen receptor degrader (HY-W248665A) ; Blue, CBP/p300 ligand (HY-161483) ; Black, Linker) [1].

• UNSPSC :

  12352005

• Target :

  Histone Acetyltransferase; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; PROTAC

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cbpd-268.html

• Purity :

  99.23

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(N1CC2=C(CC1)N([C@@H]3CC[C@H](CC3)CN4CC(C=C(C(N(C5CCC(NC5=O)=O)C6=O)=O)C6=C7)=C7C4)N=C2N8CCCC9=C8C=C(C(F)F)C(C%10=CN(N=C%10)C)=C9)=O

• Molecular Formula :

  C44H47F2N9O5

• Molecular Weight :

  819.90

• References & Citations :

  [1]Chen Z, et al. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. J Med Chem. 2024 Apr 11;67 (7) :5275-5304.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2832961-58-5]